Sarepta Therapeutics | SRPT - Umsatzkosten

Aktienkurs
20.76
Täglich Wechseln
-0.31 -1.47%
Monatlich
1.37%
Jährlich
-66.73%
Q2 Prognose
19.87




Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Insmed USD 46.16M 15.25M 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
Moderna USD 452M 245M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novavax USD 22.1M 608K 2025-12
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.67B 621M 2026-03
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12